Cargando…

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

BACKGROUND: Treatment options are limited for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after treatment failure with EGFR tyrosine kinase inhibitors (TKIs). This multicenter open-label, phase II study aims to evaluate the efficacy and safety of tislelizumab p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Hua, Zhang, Xueyan, Tian, Panwen, Chu, Tianqing, Guo, Qisen, Yu, Xinmin, Yu, Zhuang, Li, Yalun, Chen, Lijuan, Liu, Jie, Zhang, Yan, Guan, Yan, Shi, Xun, Wang, Jing, Zhao, Yanqiu, Han, Baohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441075/ https://www.ncbi.nlm.nih.gov/pubmed/37597849 http://dx.doi.org/10.1136/jitc-2023-006887

Ejemplares similares

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
por: Zhao, Jun, et al.
Publicado: (2023)

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
por: Shen, Lin, et al.
Publicado: (2020)

Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
por: Li, Fenge, et al.
Publicado: (2021)

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
por: Peng, Xiao-Xiao, et al.
Publicado: (2020)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
por: Xu, Jianlin, et al.
Publicado: (2016)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Xia, Jinjing, et al.
Publicado: (2017)

Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
por: Dettling, Danielle E, et al.
Publicado: (2022)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
por: Xu, Jianlin, et al.
Publicado: (2016)

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
por: Jin, Ying, et al.
Publicado: (2016)

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
por: Song, Yuqin, et al.
Publicado: (2022)

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
por: Loriot, Y, et al.
Publicado: (2010)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
por: Yang, Lei, et al.
Publicado: (2022)

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR sensitive mutation
por: Huang, Aimi, et al.
Publicado: (2016)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
por: Tykodi, Scott S, et al.
Publicado: (2022)

A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR
por: Al-Mayhani, Talal F, et al.
Publicado: (2019)

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017)

Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial
por: Yang, Lu, et al.
Publicado: (2018)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
por: Ready, Neal E, et al.
Publicado: (2023)

Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
por: Wang, Huan, et al.
Publicado: (2014)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

Erratum to: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
por: Wang, Huan, et al.
Publicado: (2014)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0cnncea0of53dhftumvosti82h